Predictors for survival in patients with bone metastasis of small cell lung cancer: A population-based study. Issue 34 (27th August 2021)

• Record Type: Journal Article
• Authors: Xue, MingFeng; Chen, Gang; Chen, XingGuang; Hu, JunYu
• Other Names: Vartolomei. Mihai Dorin section editor.
• Is Part Of: Medicine. Volume 100:Issue 34(2021)
• Publication Date: 2021-08-27
• Subjects: bone metastasis -- characteristics -- prognosis -- small cell lung cancer -- survival predictor; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000027070
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: The objective of the current study is to analyze the clinical and demographic characteristics of patients with bone metastasis of small cell lung cancer (SCLC) and explore their survival predictors. We retrospectively extracted patients with bone metastasis of SCLC from the Surveillance, Epidemiology, and End Results database. We applied Cox regression analyses to identify independent survival predictor of overall survival (OS) and cancer-specific survival (CSS). Only significant predictors from univariable analysis were included for multivariable Cox analysis. Kaplan–Meier method was used to evaluate survival differences between groups by the log–rank test. A total of 5120 patients with bone metastasis of SCLC were identified and included for survival analysis. The 1-year OS and CSS rates of bone metastasis of SCLC were 19.8% and 21.4%, respectively. On multivariable analysis, gender, age, radiotherapy, chemotherapy, liver metastasis, brain metastasis, insurance status, and marital status independently predicted OS and CSS. There was no significant difference of OS and CSS in terms of race and tumor size. Independent predictors of survival were identified among patients with bone metastasis of SCLC, which could be valuable to clinicians in treatment decision. Patients with bone metastasis of SCLC may benefit from radiotherapy and chemotherapy.